Cipla shares closed with a gain of 3.83 per cent on BSE today. The price of its shares has gone up to Rs 892.75.
On the first trading day of this week i.e. Monday, lakhs of crores of investors were drowned in the stock market. However, in the midst of all this, there was a jump in the shares of the pharma company Cipla. Cipla shares closed with a gain of 3.83 per cent on BSE today. The price of its shares has gone up to Rs 892.75. At the same time, talking about NSE, its shares have closed with a gain of 3.71 percent. Benchmark indices are falling continuously due to heavy selling in the global market due to the new variant of Corona virus Omicron. Today, the domestic benchmark indices Sensex and Nifty closed with a huge fall of about 2 percent. Only two stocks on the Sensex and three on the Nifty have closed with gains. All sector indices of Nifty fell today. Due to all this, the Sensex closed at 55,822.01 today with a slippage of 1189.73 points and the Nifty closed at 16,614.20 with a fall of 371.00 points.
Stock Market Fall Today: Lakhs of crores of investors drowned in two days, know why there was a huge fall in Sensex and Nifty, experts gave these suggestions
what is the reason for the jump
“Cipla and its subsidiary Cipla USA, Inc. have received final approval from the United States Food and Drug Administration (USFDA) for Lanreotide Injection,” the company said. FDA approval was based on a New Drug Application (NDA) submitted under a 505(b)(2) filing. Lanreotide injection is for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumor (GEP-NET). As per the company’s regulatory filings, it is supplied in 60 mg/0.2 ml, 90 mg/0.3 ml, and 120 mg/0.5 ml single-dose pre-filled syringes.
Share Market Closing Bell: Sensex fell by 1190 points, Nifty also weakened by 2%, Tata Steel fell 5%
Umang Vohra, MD & Global CEO, Cipla said, “We are delighted to receive the final approval for Lanreotide Injection from the USFDA. Our aim is to make it easier for people to access high quality treatments. This approval is vital to our US business.” Foreign research firm Nomura has given ‘buy’ rating to Cipla’s stock with a target of Rs 1,051 per share. Nomura expects Lanreotide Depot Injection to be launched soon. The company said, “The approval is a positive surprise.” Cipla’s stock touched a 52-week high of Rs 1,005 on September 29 this year. At the same time, on March 19, 2021, it touched a 52-week low with Rs 738.25.
(Article : Harshita Tyagi)
Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.
.